Milestone Pharma wins China OK for rapid heartbeat spray
China’s drug regulator approved etripamil nasal spray for adult PSVT, triggering a $2 million milestone and opening a royalty-bearing partnership market in Greater China for MIST.
Rhea-AI Filing Summary
Milestone Pharmaceuticals Inc. (MIST) announced that China’s National Medical Products Administration has approved etripamil nasal spray for treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, the first regulatory approval for etripamil outside the United States.
The approval triggers a $2.0 million payment to Milestone from partner Everest Medicines, which holds exclusive development and commercialization rights in Greater China. Milestone is also eligible for up to $98.0 million in additional commercial and development milestones and tiered royalties of up to 18% on future sales in Greater China. The decision was supported by Phase 3 data, including the JX02002 study in China, where etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes.
Positive
- NMPA approval in China for etripamil nasal spray in adult PSVT provides the first regulatory clearance for the drug outside the U.S. and establishes a new commercial market in Greater China.
- $2.0 million milestone payment is immediately triggered by the China approval, adding non-dilutive cash tied directly to regulatory progress.
- License agreement with Everest Medicines offers up to $98.0 million in additional commercial and development milestones plus tiered royalties up to 18% on future etripamil sales in Greater China.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Initial milestone payment: $2.0 million
Potential additional milestones: $98.0 million
Maximum royalty rate: 18%
+5 more
8 metrics
Initial milestone payment
$2.0 million
Payment to Milestone triggered by NMPA approval of etripamil in China
Potential additional milestones
$98.0 million
Commercial and development milestones possible under license agreement with Everest Medicines
Maximum royalty rate
18%
Tiered royalties on future etripamil sales in Greater China
JX02002 hazard ratio
3.002
Etripamil vs placebo for PSVT conversion to sinus rhythm within 30 minutes
JX02002 p-value
0.0005
Statistical significance of etripamil superiority over placebo in PSVT conversion
95% confidence interval for hazard ratio
1.578 to 5.711
Etripamil vs placebo in JX02002 PSVT study
Estimated PSVT patients in China
3 to 6 million
People in China currently diagnosed with PSVT
Estimated PSVT patients in U.S.
2 million
People in the United States currently diagnosed with PSVT
Key Terms
paroxysmal supraventricular tachycardia (PSVT), National Medical Products Administration (NMPA), hazard ratio, Phase 3, +2 more
6 terms
paroxysmal supraventricular tachycardia (PSVT) medical
"approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults"
National Medical Products Administration (NMPA) regulatory
"China’s National Medical Products Administration (NMPA) has approved etripamil nasal spray"
The National Medical Products Administration (NMPA) is China's national regulator that reviews and approves medicines, vaccines, medical devices and cosmetics to ensure they are safe and effective. Investors watch NMPA decisions because its approvals act like a gatekeeper or traffic light for market access—granting permission can unlock sales and growth, while delays, restrictions or rejections can limit revenue, change timelines and increase business risk.
hazard ratio medical
"demonstrating that etripamil was significantly superior to placebo ... (hazard ratio = 3.002"
A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.
Phase 3 medical
"based on data from the global pivotal Phase 3 RAPID study and the Phase 3 JX02002 study"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
atrial fibrillation with rapid ventricular rate (AFib-RVR) medical
"Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR)"
Atrial fibrillation with rapid ventricular rate (AFib‑RVR) is a heart rhythm problem where the upper chambers beat chaotically and the lower chambers respond too fast, like a car engine misfiring and revving too high. For investors, it matters because it drives urgent medical visits, hospital stays, and long‑term use of drugs, devices or procedures, so changes in incidence, treatment options, or regulatory approvals can affect healthcare costs and company revenues.
calcium channel blocker medical
"CARDAMYST (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved"
A calcium channel blocker is a type of prescription medicine that relaxes blood vessels and can slow the heart by blocking calcium’s effect on muscle cells, much like turning down the electricity to a motor to make it run more gently. For investors, these drugs matter because their safety, regulatory status, sales trends, patent life and competition directly affect pharmaceutical revenues and healthcare costs, which can influence stock value and forecasts.
FAQ
What did Milestone Pharmaceuticals (MIST) announce regarding etripamil in China?
Milestone announced that China’s National Medical Products Administration approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, marking the first regulatory approval for etripamil outside the United States.
How much milestone revenue does MIST receive from the China approval?
The NMPA approval triggers a $2.0 million payment to Milestone Pharmaceuticals from its partner Everest Medicines, under their exclusive license agreement for etripamil in Greater China.
What is the total milestone and royalty potential for MIST in Greater China?
Under its license agreement with Everest Medicines, Milestone is eligible for up to $98.0 million in commercial and development milestones and tiered royalties up to 18% on future etripamil sales in Greater China.
What key clinical data supported the NMPA approval mentioned by MIST?
The approval was supported by the global Phase 3 RAPID study and China’s Phase 3 JX02002 study, where etripamil showed superior conversion of PSVT to sinus rhythm within 30 minutes versus placebo (hazard ratio 3.002; p = 0.0005).
How large is the potential PSVT patient population referenced by MIST?
Milestone cites an estimated three to six million people with PSVT in China and about two million in the United States, highlighting a substantial potential market for etripamil/CARDAMYST therapy.
Who will commercialize etripamil in Greater China for MIST?
Everest Medicines holds an exclusive license to develop and commercialize etripamil nasal spray in Greater China, including Mainland China, Hong Kong, Macau and Taiwan, and will lead commercialization in these markets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
